Intelligent Bio Solutions (INBS, Financial) has successfully expanded its partnership with Spjotgard, enhancing the reach of its Fingerprinting Drug Screening System in Scandinavia. This collaboration is effectively propelling the system's adoption in Sweden, Norway, and Denmark and is sparking interest in Finland. The fingerprint-based testing method is gaining attention as a preferred alternative to traditional saliva and urine testing. It is particularly favored in sectors such as workplace safety and education, where hygiene, ease of use, and minimal invasiveness are essential. The fingerprint method maintains accuracy while offering substantial time savings and reducing operational disruptions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Intelligent Bio Solutions Inc (INBS, Financial) is $12.00 with a high estimate of $12.00 and a low estimate of $12.00. The average target implies an upside of 574.16% from the current price of $1.78. More detailed estimate data can be found on the Intelligent Bio Solutions Inc (INBS) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Intelligent Bio Solutions Inc's (INBS, Financial) average brokerage recommendation is currently 1.0, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
